Senseonics (NYSEAMERICAN:SENS) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Senseonics (NYSEAMERICAN:SENS) in a research note issued to investors on Tuesday morning, The Fly reports. The firm issued a buy rating and a $2.00 target price on the stock.

A number of other analysts have also recently commented on SENS. Raymond James cut shares of Senseonics from an outperform rating to a market perform rating in a research note on Friday, July 5th. BTIG Research reiterated a buy rating and issued a $2.00 target price on shares of Senseonics in a research note on Sunday, August 11th. Finally, Piper Jaffray Companies set a $2.00 target price on shares of Senseonics and gave the stock a hold rating in a research note on Wednesday, September 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $2.00.

Senseonics stock opened at $1.01 on Tuesday. The firm has a 50-day moving average price of $1.07 and a 200-day moving average price of $1.79. Senseonics has a 12-month low of $0.80 and a 12-month high of $4.05.

Senseonics (NYSEAMERICAN:SENS) last released its earnings results on Wednesday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). The firm had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $4.52 million.

In other Senseonics news, CEO Timothy T. Goodnow acquired 88,500 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was acquired at an average cost of $1.10 per share, for a total transaction of $97,350.00. Insiders own 34.10% of the company’s stock.

Several large investors have recently bought and sold shares of SENS. BlackRock Inc. grew its holdings in shares of Senseonics by 19.3% during the second quarter. BlackRock Inc. now owns 7,081,114 shares of the company’s stock worth $14,445,000 after buying an additional 1,145,232 shares in the last quarter. Vanguard Group Inc. lifted its position in Senseonics by 2.1% in the second quarter. Vanguard Group Inc. now owns 5,285,943 shares of the company’s stock valued at $10,783,000 after buying an additional 110,432 shares during the last quarter. Polar Asset Management Partners Inc. lifted its position in Senseonics by 2.5% in the second quarter. Polar Asset Management Partners Inc. now owns 3,310,000 shares of the company’s stock valued at $6,752,000 after buying an additional 81,451 shares during the last quarter. Invesco Ltd. acquired a new position in Senseonics in the second quarter valued at about $4,416,000. Finally, Northern Trust Corp lifted its position in Senseonics by 2.7% in the second quarter. Northern Trust Corp now owns 1,023,395 shares of the company’s stock valued at $2,088,000 after buying an additional 26,906 shares during the last quarter. 30.66% of the stock is owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

See Also: Stop Order

The Fly

Analyst Recommendations for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit